TW202519217A - 心臟肌小節抑制劑口服調配物 - Google Patents

心臟肌小節抑制劑口服調配物 Download PDF

Info

Publication number
TW202519217A
TW202519217A TW113138679A TW113138679A TW202519217A TW 202519217 A TW202519217 A TW 202519217A TW 113138679 A TW113138679 A TW 113138679A TW 113138679 A TW113138679 A TW 113138679A TW 202519217 A TW202519217 A TW 202519217A
Authority
TW
Taiwan
Prior art keywords
weight
core
intragranular
cellulose
sodium
Prior art date
Application number
TW113138679A
Other languages
English (en)
Chinese (zh)
Inventor
喬春生
Original Assignee
美商胞質動力學公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商胞質動力學公司 filed Critical 美商胞質動力學公司
Publication of TW202519217A publication Critical patent/TW202519217A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW113138679A 2019-07-17 2020-07-16 心臟肌小節抑制劑口服調配物 TW202519217A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962875358P 2019-07-17 2019-07-17
US62/875,358 2019-07-17

Publications (1)

Publication Number Publication Date
TW202519217A true TW202519217A (zh) 2025-05-16

Family

ID=71995104

Family Applications (2)

Application Number Title Priority Date Filing Date
TW113138679A TW202519217A (zh) 2019-07-17 2020-07-16 心臟肌小節抑制劑口服調配物
TW109124113A TWI917329B (zh) 2019-07-17 2020-07-16 心臟肌小節抑制劑口服調配物

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW109124113A TWI917329B (zh) 2019-07-17 2020-07-16 心臟肌小節抑制劑口服調配物

Country Status (24)

Country Link
US (1) US20220265612A1 (cg-RX-API-DMAC7.html)
EP (1) EP3999038B1 (cg-RX-API-DMAC7.html)
JP (1) JP7623342B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220082804A (cg-RX-API-DMAC7.html)
CN (1) CN114765954B (cg-RX-API-DMAC7.html)
AU (1) AU2020315642B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022000495A2 (cg-RX-API-DMAC7.html)
CL (1) CL2022000108A1 (cg-RX-API-DMAC7.html)
DK (1) DK3999038T3 (cg-RX-API-DMAC7.html)
ES (1) ES2974542T3 (cg-RX-API-DMAC7.html)
FI (1) FI3999038T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20240200T1 (cg-RX-API-DMAC7.html)
HU (1) HUE065712T2 (cg-RX-API-DMAC7.html)
IL (1) IL289884B2 (cg-RX-API-DMAC7.html)
LT (1) LT3999038T (cg-RX-API-DMAC7.html)
MX (1) MX2022000708A (cg-RX-API-DMAC7.html)
PH (1) PH12022550083A1 (cg-RX-API-DMAC7.html)
PL (1) PL3999038T3 (cg-RX-API-DMAC7.html)
PT (1) PT3999038T (cg-RX-API-DMAC7.html)
RS (1) RS65302B1 (cg-RX-API-DMAC7.html)
SI (1) SI3999038T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400107T1 (cg-RX-API-DMAC7.html)
TW (2) TW202519217A (cg-RX-API-DMAC7.html)
WO (1) WO2021011808A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202006296YA (en) 2018-01-19 2020-08-28 Cytokinetics Inc Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス, インコーポレイテッド 心臓サルコメア阻害剤
EP3814343B1 (en) 2018-06-26 2023-01-11 Cytokinetics, Inc. Cardiac sarcomere inhibitors
MA53491A (fr) 2018-08-31 2021-09-15 Cytokinetics Inc Inhibiteurs de sarcomes cardiaques
MX2022000498A (es) 2019-07-17 2022-02-03 Cytokinetics Inc Polimorfos de (r)-n-(5-(5-isopropil-1,2,4-oxadiazol-3-il)-2,3-dihi dro-1h-inden-1-il) -2-metil-2h- tetrazol-5-carboxamida.
KR20240015622A (ko) 2021-03-04 2024-02-05 싸이토키네틱스, 인코포레이티드 심장 근절 억제제
EP4370116B1 (en) 2021-07-16 2025-01-15 Cytokinetics, Inc. Aficamten dosage regimens for treating obstructive hypertrophic cardiomyopathy
US20240091203A1 (en) 2022-07-20 2024-03-21 Cytokinetics, Incorporated Methods for treating non-obstructive hypertrophic cardiomyopathy
JP2025525913A (ja) 2022-08-04 2025-08-07 サイトキネティックス, インコーポレイテッド 閉塞性肥大型心筋症を治療するための方法
CN120712262A (zh) * 2023-03-02 2025-09-26 苏州科睿思制药有限公司 Aficamten的共晶及其制备方法和用途
WO2025198687A1 (en) 2024-03-20 2025-09-25 Cytokinetics, Incorporated Methods for treating heart diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006284751A1 (en) * 2005-09-01 2007-03-08 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
CA2772275A1 (en) * 2009-09-18 2011-03-24 Sanofi (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
US20130273096A1 (en) * 2011-10-05 2013-10-17 Bruce A. Daniels Therapeutic Sulfated Polysaccharides, Compositions Thereof, and Methods for Treating Patients
NZ727015A (en) * 2012-01-25 2017-12-22 Vertex Pharma Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
US9199945B2 (en) * 2013-06-21 2015-12-01 MyoKardia, Inc. Cycloalkyl-substituted pyrimidinedione compounds
EP3151671A4 (en) * 2014-06-03 2018-03-07 Sulfagenix, Inc. Methods and compositions for treating nitric oxide deficiency disorders and related conditions
US9902702B2 (en) * 2014-07-15 2018-02-27 Bristol-Myers Squibb Company Spirocycloheptanes as inhibitors of rock
DK3356345T3 (da) * 2015-09-30 2024-02-12 Max Planck Gesellschaft Heteroaryl-derivater som sepiapterin-reduktase-inhibitorer
SG11202006296YA (en) * 2018-01-19 2020-08-28 Cytokinetics Inc Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors

Also Published As

Publication number Publication date
AU2020315642B2 (en) 2026-04-02
MX2022000708A (es) 2022-02-23
AU2020315642A1 (en) 2022-03-03
CN114765954B (zh) 2024-01-02
NZ784934A (en) 2025-03-28
JP2022542804A (ja) 2022-10-07
EP3999038B1 (en) 2024-01-10
PH12022550083A1 (en) 2023-04-12
IL289884B1 (en) 2025-09-01
RS65302B1 (sr) 2024-04-30
JP7623342B2 (ja) 2025-01-28
IL289884B2 (en) 2026-01-01
DK3999038T3 (da) 2024-03-18
CN114765954A (zh) 2022-07-19
WO2021011808A1 (en) 2021-01-21
ES2974542T3 (es) 2024-06-27
SI3999038T1 (sl) 2024-05-31
CL2022000108A1 (es) 2022-10-21
IL289884A (en) 2022-03-01
LT3999038T (lt) 2024-03-25
TW202116307A (zh) 2021-05-01
EP3999038A1 (en) 2022-05-25
HUE065712T2 (hu) 2024-06-28
BR112022000495A2 (pt) 2022-03-03
PL3999038T3 (pl) 2024-05-13
HRP20240200T1 (hr) 2024-04-26
TWI917329B (zh) 2026-03-11
SMT202400107T1 (it) 2024-05-14
CA3144972A1 (en) 2021-01-21
US20220265612A1 (en) 2022-08-25
PT3999038T (pt) 2024-03-14
KR20220082804A (ko) 2022-06-17
FI3999038T3 (fi) 2024-02-21

Similar Documents

Publication Publication Date Title
JP7623342B2 (ja) 心臓サルコメア阻害剤の経口用製剤
US11384053B2 (en) Heterocyclic compounds and their uses
TWI865562B (zh) (r)-n-(5-(5-乙基-1,2,4-二唑-3-基)-2,3-二氫-1h-茚-1-基)-1-甲基-1h-吡唑-4-羧醯胺之多晶型物
US20150005350A1 (en) Administration of ethyl 3-[(2--1-methyl-1h-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionate
NO332209B1 (no) Etyl-3-[(2-{[4-(heksyloksykarbonyl¬amino-imino-metyl)-fenylamino]-metyl}-1-metyl-1H-benzimidazol-5-karbonyl)-pyridin-2-yl-amino]-propionat- metansulfonat
US20150164854A1 (en) Formulations of histone deacetylase inhibitor and uses therof
JP5968927B2 (ja) 高血圧と代謝症候群の治療に用いられる薬物組成物及びその応用
EP3999181B1 (en) Polymorphs of (r)-n-(5-(5-isopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-2-methyl-2h-tetrazole-5-carboxamide
ES2616405T3 (es) Formulaciones de comprimidos de liberación inmediata de una antagonista del receptor de trombina
JP2025523921A (ja) 非閉塞性肥大型心筋症を治療するための方法
TW202423424A (zh) 治療阻塞型肥厚性心肌病之方法
CN109640989A (zh) 用于治疗神经性起立性低血压的化合物
CN121218995A (zh) 包含一或多种sglt-2抑制剂及匹莫苯丹和/或替米沙坦的非人类哺乳动物中心脏疾病的组合治疗和/或预防
US20230040902A1 (en) Pharmaceutical Formulation Comprising Cibenzoline or Salt Thereof
RU2823999C2 (ru) Пероральные композиции ингибиторов сердечного саркомера
JP5925862B2 (ja) セロトニン受容体介在状態を治療する方法及び組成物
HK40077275A (en) Cardiac sarcomere inhibitor oral formulations
HK40077275B (zh) 心脏肌节抑制剂口服制剂
CN100413539C (zh) 5-ht4受体拮抗剂在制备治疗电生理心房改型的药物中的应用
RU2846046C2 (ru) Полиморфы (r)-n-(5-(5-этил-1,2,4,-оксадиазол-3-ил)-2,3-дигидро-1н-инден-1-ил)-1-метил-1н-пиразол-4-карбоксамида
JP6903252B2 (ja) キサンチンオキシダーゼ阻害剤含有腸溶性製剤
HK40122886A (en) Methods for treating non-obstructive hypertrophic cardiomyopathy
CN101297807A (zh) 5-ht4受体拮抗剂在预防或治疗某些心血管疾病中的应用